Yahoo Finance • 2 months ago
Legend Biotech USA Inc. New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Bi... Full story
Yahoo Finance • 5 months ago
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study e... Full story
Yahoo Finance • 9 months ago
CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment SOMERSET, N.J., February 23, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (N... Full story
Yahoo Finance • 9 months ago
SOMERSET, N.J., February 13, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening disease... Full story
Yahoo Finance • 11 months ago
SOMERSET, N.J., January 03, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases... Full story
Yahoo Finance • 11 months ago
In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story
Yahoo Finance • 12 months ago
Insight into the Latest 13F Filing Reveals Significant Portfolio Changes Matthews Emerging Markets Small Companies Fund (Trades, Portfolio), known for its strategic investments in Asia's burgeoning small-cap market, has revealed its 13F h... Full story
Yahoo Finance • last year
Legend Biotech Corporation (the "Company" or Legend Biotech), through its wholly owned subsidiary, Legend Biotech Ireland Limited, entered into an exclusive, global license agreement with Novartis Pharma AG. The Company granted Novartis th... Full story
Yahoo Finance • last year
The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the Novartis next-generation T-Charge™ C... Full story
Yahoo Finance • last year
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a... Full story
Yahoo Finance • last year
The Matthews Emerging Markets Small Companies fund has delivered a 15.1% annualized three-year return, landing it in the top 1% of its peers. Here’s what manager Vivek Tanneeru is buying now.... Full story
Yahoo Finance • 2 years ago
Farewell, July, it’s been a pleasure. Sentiment might finally be turning on Wall Street after the stock market recorded its best month since November 2020, buoyed by the tech giants better-than-expected quarterly results and the prospect o... Full story
Yahoo Finance • 3 years ago
With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.... Full story
Yahoo Finance • 3 years ago
(Adds background on Legend, CAR-T therapies) March 25 (Reuters) - The European Medicines Agency on Friday recommended the use of Johnson & Johnson and its partner Legend Biotech Corp's CAR-T therapy to treat multiple myeloma, nearly a mon... Full story